TrialDiabetes2004

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Kristine B Degn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.